secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eikon Therapeutics, Inc. (EIKN)
CIK:        0001861123
Form:       8-K
Filed at:   2026-05-11T20:05:32+00:00
Accession:  0001193125-26-216744
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eikon Therapeutics Q1 2026 net loss $83M, cash $596M; three oncology programs advance
--------------------------------------------------------------------------------

- Net loss $83M (Q1 2026) vs $74.5M (Q1 2025); R&D expenses $70M (+24%) incl. $5M milestone to Impact Therapeutics.
- Cash, equivalents and marketable securities $596M at March 31, 2026; expected to fund operations into H2 2027.
- EIK1001: Phase 2 NSCLC trial fully enrolled; updated data at ASCO; Phase 2/3 trials in melanoma and NSCLC initiated.
- EIK1003: Dose escalation completed; Phase 2 dose optimization trial first patient dosed; global site selection for Cohort 1D started.
- EIK1005 (WRN helicase inhibitor): Phase 1/2 trial began dosing Feb 2026; two abstracts accepted for ASCO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861123/000119312526216744/0001193125-26-216744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861123/000119312526216744/eikn-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer